-
REAL-WORLD CHARACTERISTICS AND ADVANCED THERAPY USE IN U.S. PATIENTS WITH MODERATE-SEVERE TREATMENT RESISTANT DEPRESSION (TRD)
Aug 11, 2026, 17:16 PM -
BUILDING AN INTEGRATED MODELING PLATFORM IN R SHINY FOR EARLY ECONOMIC EVALUATION IN ONCOLOGY
Aug 11, 2026, 17:16 PM -
AN AGENTIC WORKFLOW FOR DEVELOPING HIGH-SENSITIVITY PUBMED SEARCH STRATEGIES FOR EVIDENCE SYNTHESIS
Aug 11, 2026, 17:16 PM -
TIME-VARYING EXUDATE SEVERITY AND DELAYED HEALING IN PRESSURE INJURIES: A REAL-WORLD COHORT ANALYSIS
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF A DYNAMIC CTDNA-GUIDED ADJUVANT STRATEGY IN STAGE II-III COLON CANCER. A SAGITTARIUSMODEL-BASED ANALYSIS
Aug 11, 2026, 17:16 PM -
THE CAPTURED TRIAL: CAN ALGORITHMS AND QUALITY IMPROVEMENT SUPPORT FOR PRIMARY CARE LEAD TO EARLIER DIAGNOSIS FOR SPECIFIC RARE DISEASE PATIENTS?
Aug 11, 2026, 17:16 PM -
EARLY ECONOMIC EVALUATION OF A PHARMACIST-LED INTERVENTION TO IMPROVE MEDICATION USE IN PATIENTS WITH CHRONIC HEART FAILURE
Aug 11, 2026, 17:16 PM -
PRODUCTIVITY LOSSES AND HEALTHCARE RESOURCE UTILISATION: A COMPARISON BETWEEN PATIENTS WITH CIDP AND THE GENERAL POPULATION
Aug 11, 2026, 17:16 PM -
NATURAL HISTORY MODELING OF ALL-CAUSE DECOMPENSATED CIRRHOSIS: LONG-TERM CLINICAL AND ECONOMIC BURDEN AND CONSIDERATIONS FOR FUTURE ECONOMIC EVALUATIONS
Aug 11, 2026, 17:16 PM -
THE ECONOMIC AND SOCIAL BURDEN OF OBESITY IN BULGARIA
Aug 11, 2026, 17:16 PM -
STAKEHOLDER PERCEPTIONS ON THE ADOPTION OF VALUE-BASED HEALTHCARE (VBHC) AND INNOVATIVE CONTRACTING MODELS IN THE KINGDOM OF SAUDI ARABIA: A QUALITATIVE ANALYSIS
Aug 11, 2026, 17:16 PM -
IMMATURE OVERALL SURVIVAL DATA IN FRENCH HTA: WHAT DIFFERENTIATES ASMR III FROM ASMR IV RATINGS?
Aug 11, 2026, 17:16 PM -
REGULATORY APPROVAL AND PATIENT ACCESS TIMELINES IN THE US AND EUROPE: A BASELINE ANALYSIS TO INFORM POTENTIAL EFFECTS OF MOST-FAVOURED-NATION PRICING POLICIES
Aug 11, 2026, 17:16 PM -
INDIRECT TREATMENT COMPARISONS IN EU JOINT CLINICAL ASSESSMENT: ALIGNED WITH INTERNATIONAL GOOD PRACTICE?
Aug 11, 2026, 17:16 PM -
EFFECTS OF CHINA'S NATIONAL VOLUME-BASED PROCUREMENT ON DRUG AFFORDABILITY, UTILIZATION, AND SUBSTITUTION: A STRUCTURED EVIDENCE SYNTHESIS
Aug 11, 2026, 17:16 PM -
PROJECTED VS. REAL PHARMACEUTICAL EXPENDITURE IN GERMANY: A RETROSPECTIVE ANALYSIS OF THE PRICE AND VOLUME EFFECTS
Aug 11, 2026, 17:16 PM -
BENCHMARKING AI-SUPPORTED EVIDENCE SYNTHESIS TOOLS FOR HEALTH TECHNOLOGY ASSESSMENT (HTA) EVIDENCE GENERATION: A COMPARATIVE ASSESSMENT ACROSS THE EVIDENCE LIFECYCLE
Aug 11, 2026, 17:16 PM -
FROM EUROPEAN JOINT CLINICAL ASSESSMENT TO NATIONAL REIMBURSEMENT: EARLY EXPERIENCE FROM IRELAND
Aug 11, 2026, 17:16 PM -
TRENDS IN PARP INHIBITOR UTILISATION BEFORE AND AFTER REASSESSMENT IN THE NETHERLANDS
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS ASSESSMENT OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV20) AMONG OLDER ADULTS IN THE PHILIPPINES
Aug 11, 2026, 17:16 PM
